Objective: To evaluate the clinical efficacy of Ambroxol combined with Cefoperazone and Tazobactam in the treatment of elderly community acquired pneumonia (CAP). Methods: A total of 82 patients with CAP were randomly divided into treatment group (n=4l) and control group (n=4l). The treatment group was administered with Ambroxol combined with Cefoperazone and Tazobactam, and control group was singly administered with Cefoperazone and Tazobactam, all patients were treated for 10 days, the time of improved clinical symptoms, clinical efficacy and adverse drug reactions (ADR) were ob -served and compared. Results: The effective rate of treatment group and control group was 92.68% and 70.73% respectively, which showed a statistical difference (χ2= 12.430, P<0.05). In the treatment group, the clinical symptoms of cough and expectoration, fever and rale was (6.5 ±1.2) d, (3.0±1.3) d and (6.9 ±1.1) d respectively, and that in control group was (8.2 ± 0.4) d, (5.9±1.0) d and (8.5+1.3) d respectively, which showed statistical differences (P<0.05). No ADR was observed in both groups. Conclusion: Ambroxol combined with Cefoperazone and Tazobactam is safe and effective in the treatment of elderly CAP, and it is worthy to be widely used in the clinical.%目的:评价氨溴索联合头孢哌酮他唑巴坦治疗老年社区获得性肺炎(CAP)的临床疗效.方法:将82例老年CAP患者随机分为治疗组(41例)和对照组(41例).治疗组给予氨溴索联合头孢哌酮他唑巴坦治疗,对照组仅给予头孢哌酮他唑巴坦治疗,治疗10 d后,观察两组临床症状改善起效时间、疗效及不良反应情况.结果:治疗组有效率为92.68%,显著高于对照组(70.73%),差异有统计学意义(χ2=12.430,P＜0.05).治疗组咳嗽、咳痰,发热,肺部啰音等临床症状改善起效时间分别为(6.5±1.2)d,(3.0±1.3)d,(6.9±1.1)d,均较对照组[(8.2±0.4)d,(5.9±1.0)d,(8.5±1.3)d]短,差异均有统计学意义(均P＜0.05).两组均未发生药物相关不良反应.结论:氨溴索联合头孢哌酮他唑巴坦治疗老年CAP疗效显著,用药安全,值得临床推广使用.
展开▼
